Investing.com - Quest Diagnostics (NYSE:DGX) reported on Thursday second quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Quest Diagnostics announced earnings per share of $2.36 on revenue of $2.45B. Analysts polled by Investing.com anticipated EPS of $2.24 on revenue of $2.32B.
Quest Diagnostics shares are down 15% from the beginning of the year and are trading at $137.34 , down-from-52-week-high.They are outperforming the S&P 500 which is down 16.92% from the start of the year.
Quest Diagnostics shares gained 1.85% in pre-market trade following the report.
Quest Diagnostics follows other major Healthcare sector earnings this month
Quest Diagnostics's report follows an earnings beat by UnitedHealth on Friday, July 15, 2022, who reported EPS of $5.57 on revenue of $80.33B, compared to forecasts EPS of $5.21 on revenue of $79.68B.
J&J had beat expectations on Tuesday with second quarter EPS of $2.59 on revenue of $24.02B, compared to forecast for EPS of $2.55 on revenue of $23.8B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar